Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: China's 3SBio in-licenses second PharmAbcine mAb

    PharmAbcine Inc. (Daejon, South Korea) granted 3SBio Inc. (Shenyang, China) an exclusive license to develop DIG-KT (TRPH 011) in greater China and Korea. The bispecific antibody against vascular endothelial growth …

    Published on 1/15/2015
  • COMPANY NEWS: Depomed buys Janssen's Nucynta analgesics for $1.1B

    Depomed Inc. (NASDAQ:DEPO) acquired U.S. rights to the Nucynta tapentadol analgesic franchise from the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) for $1.1 billion. The deal includes extended-…

    Published on 1/15/2015
  • COMPANY NEWS: India patent office rejects Gilead's Sovaldi application

    The Indian Patent Office rejected an application from Gilead Sciences Inc. (NASDAQ:GILD) for a patent covering HCV drug Sovaldi sofosbuvir. The patent office issued a decision saying Sovaldi did not offer "significantly…

    Published on 1/15/2015
  • COMPANY NEWS: NICE extends recommendations for Sovaldi, Olysio

    The U.K.'s NICE extended earlier draft recommendations for Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) and Olysio simeprevir from Medivir AB (SSE:MVIR B) and Johnson & Johnson (NYSE:JNJ) to include …

    Published on 1/15/2015
  • COMPANY NEWS: Genentech, Human Longevity in sequencing tie-up

    The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) partnered with genome sequencing company Human Longevity Inc. (San Diego, Calif.) to identify new therapeutic targets and diagnostic biomarkers.Human Longevity …

    Published on 1/14/2015
  • COMPANY NEWS: Tobira finds its public path

    Tobira Therapeutics Inc. (San Francisco, Calif.) will acquire Regado Biosciences Inc. (NASDAQ:RGDO) through a reverse merger. The combined company, which will be named Tobira Therapeutics and continue to trade on NASDAQ…

    Published on 1/14/2015
  • COMPANY NEWS: Antares dips on FDA request for testosterone safety data

    Antares Pharma Inc. (NASDAQ:ATRS) shed $0.15 to $2.46 on Tuesday after FDA told the company to expand its safety database related to QuickShot Testosterone, which is being tested in a Phase III trial to treat …

    Published on 1/13/2015
  • COMPANY NEWS: Arrowhead holds losses after partial clinical hold

    Arrowhead Research Corp. (NASDAQ:ARWR) dipped a further $0.58 to $6.32 on Tuesday, a day after it said FDA verbally informed the company of a partial clinical hold on a forthcoming Phase IIb trial of ARC-520 to treat …

    Published on 1/13/2015
  • COMPANY NEWS: Intercept provides OCA clinical update

    Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) gained $6.78 to $152.70 on Tuesday after updating investors on its clinical development plans for OCA obeticholic acid to treat liver diseases.In December, Intercept began …

    Published on 1/13/2015
  • COMPANY NEWS: Janssen licenses Vedanta's microbiome candidate for IBD

    Microbiome company Vedanta Biosciences Inc. (Boston, Mass.) granted the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) an exclusive, worldwide license to develop and commercialize microbiome therapy VE-…

    Published on 1/13/2015
  • COMPANY NEWS: More padding for Moderna's coffers

    Merck & Co. Inc. (NYSE:MRK) partnered with Moderna Therapeutics Inc. (Cambridge, Mass.) to discover and develop mRNA-based vaccines and passive immunity treatments against four undisclosed viruses.Under the three-year …

    Published on 1/13/2015
  • COMPANY NEWS: Roche licenses antibiotic from Meiji, Fedora

    Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) and Fedora Pharmaceuticals Inc. (Edmonton, Alberta) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights outside of Japan to develop and commercialize OP0595 (FPI-…

    Published on 1/13/2015
  • COMPANY NEWS: AC Immune gets another tau deal in AD

    AC Immune S.A. (Lausanne, Switzerland) granted the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) an exclusive worldwide license to develop and commercialize anti-tau vaccine candidate ACI-35 to treat…

    Published on 1/12/2015
  • COMPANY NEWS: Biogen converges on Convergence

    Biogen Idec Inc. (NASDAQ:BIIB) will acquire neuropathic pain play Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) for $200 million up front. Convergence shareholders are eligible for up to $475 million in undisclosed…

    Published on 1/12/2015
  • COMPANY NEWS: Biosimilar siege on Amgen continues

    Hospira Inc. (NYSE:HSP) said it submitted a BLA to FDA for Retacrit, its proposed biosimilar of anemia drug Epogen epoetin alfa from Amgen Inc. (NASDAQ:AMGN) and Procrit epoetin alfa from the Janssen Biotech unit of …

    Published on 1/12/2015
  • COMPANY NEWS: Celgene snatches another Agios asset

    Celgene Corp. (NASDAQ:CELG) exercised an option to license exclusive ex-U.S. rights to AG-120 from Agios Pharmaceuticals Inc. (NASDAQ:AGIO). The inhibitor of mutated isocitrate dehydrogenase 1 (IDH1) is in Phase I …

    Published on 1/12/2015
  • COMPANY NEWS: EMA accepts alirocumab MAA

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY) said Monday that EMA accepted for review their MAA for Praluent alirocumab to treat hypercholesterolemia. The companies also revealed that…

    Published on 1/12/2015
  • COMPANY NEWS: HBV play OnCore to merge with Tekmira

    Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) surged $8.98 (57%) to $24.68 on Monday after announcing plans to merge with OnCore Biopharma Inc. (Doylestown, Pa.). Under the proposed merger, OnCore would become a …

    Published on 1/12/2015
  • COMPANY NEWS: Prime picks both in HCV

    Prime Therapeutics LLC (Eagan, Minn.) is the latest pharmacy benefit manager to wade into the HCV price war. On Monday, the PBM said it would cover both Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:…

    Published on 1/12/2015
  • COMPANY NEWS: Roche takes majority stake in Foundation Medicine

    Foundation Medicine Inc. (NASDAQ:FMI) rose $22.81 (95%) to $46.74 on news that Roche (SIX:ROG; OTCQX:RHHBY) will acquire 52.4% to 56.3% of the company through a $1 billion cash and stock deal. Roche will pay $780 …

    Published on 1/12/2015
  • COMPANY NEWS: FDA approves Daiichi's Savaysa with boxed warning

    FDA approved an NDA from Daiichi Sankyo Co. Ltd. (Tokyo:4568) for once-daily 15, 30 and 60 mg Savaysa edoxaban to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) …

    Published on 1/9/2015
  • COMPANY NEWS: Legal Tracks

    Andrew Goodman rejoined Goodwin Procter as a partner in its Technology & Life Sciences Group in New York. Goodman most recently was a partner at Kean Miller LLP. Previously, he was a partner in Goodwin Procter's Los …

    Published on 1/9/2015
  • COMPANY NEWS: One year later, Agenus hits home run with Incyte deal

    Shares of Agenus Inc. (NASDAQ:AGEN) jumped $1.18 (29%) to $5.30 on Friday, adding $82.6 million in market cap, after the company entered a five-year collaboration with Incyte Corp. (NASDAQ:INCY) to develop and …

    Published on 1/9/2015
  • COMPANY NEWS: Shanghai Fosun boosts R&D budget for innovation

    Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) expects to spend more than RMB5 billion ($803.5 milllion) on R&D over a five-year period spanning 2016-20.Fosun said it spent RMB1.5 billion ($…

    Published on 1/9/2015
  • COMPANY NEWS: FDA approves Impax's Rytary for Parkinson's

    Impax Laboratories Inc. (NASDAQ:IPXL) jumped $3.61 (12%) to $34.60 on Thursday after FDA approved the company's Rytary extended release carbidopa/levodopa to treat Parkinson's disease (PD). Spokesperson Mark Donohue …

    Published on 1/8/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993